Amirabbas Rostami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amirabbas Rostami has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Ehsan Ranjbar
Department of Urology, Uro‐Oncology Research Center Tehran University of Medical Sciences Tehran Iran
1 shared publication- Fatemeh Ezzatifar
Molecular and Cell Biology Research Center, Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication - Ji Xu
Department of Rehabilitation Medicine, 3201 Hospital, Hanzhong 723000, China
1 shared publication Mina Farrokhian
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
1 shared publication- Morteza Akbari
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Navid Shomali
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication
Latest Publications
- Open Access
- 20 September 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (18) , e70077
Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management
In addressing the challenges of lung cancer, attention has increasingly turned to molecular diagnostics and targeted therapies, with nucleolin (NCL) assuming a pivotal role, especially in non‐small cell lung cancer. The aberrant activity and cellular distribution of NCL act as crucial biomarkers for early detection and treatment monitoring, showing a strong correlation with disease progression and patient prognosis. Elevated NCL levels signal advanced disease and poorer outcomes, underscoring its significance in evaluating disease severity and therapeutic response. Strategies targeting the molecular interactions of NCL have spurred innovative approaches to inhibit tumour growth, overcome drug resistance and improve treatment efficacy. These advancements are paving the way for personalized therapies tailored to the unique molecular profiles of patients' tumours. Consequently, NCL stands at the forefront of lung cancer management, symbolizing the move towards more precise and individualized oncology care, and marking substantial progress in therapeutic development.
- 20 September 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (18) , e70077
Open AccessBeyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management
In addressing the challenges of lung cancer, attention has increasingly turned to molecular diagnostics and targeted therapies, with nucleolin (NCL) assuming a pivotal role, especially in non‐small cell lung cancer. The aberrant activity and cellular distribution of NCL act as crucial biomarkers for early detection and treatment monitoring, showing a strong correlation with disease progression and patient prognosis. Elevated NCL levels signal advanced disease and poorer outcomes, underscoring its significance in evaluating disease severity and therapeutic response. Strategies targeting the molecular interactions of NCL have spurred innovative approaches to inhibit tumour growth, overcome drug resistance and improve treatment efficacy. These advancements are paving the way for personalized therapies tailored to the unique molecular profiles of patients' tumours. Consequently, NCL stands at the forefront of lung cancer management, symbolizing the move towards more precise and individualized oncology care, and marking substantial progress in therapeutic development.